Acorda Therapeutics’ Strategic Bankruptcy and Asset Sale Plan

An update from Acorda Therapeutics (ACOR) is now available.

Acorda Therapeutics, Inc. has initiated voluntary Chapter 11 proceedings and is working to sell its assets for $185 million to Merz Pharmaceuticals, LLC, subject to higher bids and court approval. Concurrently, the company has secured debtor-in-possession financing to maintain operations, with terms including a $60 million credit facility. These strategic moves aim to stabilize the company’s operations while they navigate through bankruptcy and restructuring efforts.

See more insights into ACOR stock on TipRanks’ Stock Analysis page.